SEC Filing Summary: BioSig Technologies, Inc. (BSGM)
Business Context and Reporting Period
This Form 8-K Current Report was filed by BioSig Technologies, Inc. on March 19, 2021. The registrant is a Delaware corporation with principal executive offices in Westport, Connecticut, and its common stock trades on the NASDAQ Capital Market under the symbol BSGM.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or performance metrics.
Material Changes
No material financial changes versus a prior comparable period are reported in this document. The filing serves solely to disclose a scheduled corporate event.
Guidance, Outlook, and Management Commentary
On March 19, 2021, the Company issued a press release (Exhibit 99.1) announcing that Kenneth L. Londoner, Chairman and CEO, is scheduled to present at the Benzinga Biotech Small Cap Conference on March 25, 2021, at 12:20 PM ET on track 2. The Company explicitly states it undertakes no obligation to update, supplement, or amend the materials attached. The information is furnished under Regulation FD but is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Key Facts for Investor Verification
- Verify the date and time of the CEO's presentation at the Benzinga Biotech Small Cap Conference (March 25, 2021, 12:20 PM ET).
- Confirm that this 8-K filing contains no financial data or updated guidance.
- Note that the press release attached as Exhibit 99.1 is not incorporated by reference into other Exchange Act filings unless expressly stated.